MIGUEL ÁNGEL
TEJADA GIRÁLDEZ
PROGRAMA JUAN DE LA CIERVA
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (2)
2022
-
Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer
Science Translational Medicine, Vol. 14, Núm. 660
2020
-
Urinary bladder sigma-1 receptors: A new target for cystitis treatment
Pharmacological Research, Vol. 155